AU2001266033A1 - Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base - Google Patents

Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base

Info

Publication number
AU2001266033A1
AU2001266033A1 AU2001266033A AU6603301A AU2001266033A1 AU 2001266033 A1 AU2001266033 A1 AU 2001266033A1 AU 2001266033 A AU2001266033 A AU 2001266033A AU 6603301 A AU6603301 A AU 6603301A AU 2001266033 A1 AU2001266033 A1 AU 2001266033A1
Authority
AU
Australia
Prior art keywords
formulation
heparinoid
glycosaminoglycan
heparin
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001266033A
Inventor
Jorg Breitenbach
Robert Heger
Dieter Herr
Volker Laux
Jorg Rosenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of AU2001266033A1 publication Critical patent/AU2001266033A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention relates to formulations based on at least one heparin, glycosaminoglycan or heparinoid and on a formulation base with a lipid component and a polymer component. The use of this formulation as drug form for oral administration of at least one heparin, glycosaminoglycan or heparinoid, and also a process for producing the formulations by mixing the formulation components to form a plastic mixture and, where appropriate, to manufacture the formulations as drug form, advantageously using melt extrusion, are described. The lipid component advantageously has active ingredient-promoting properties, while the polymer component is soluble or swellable. At least parts of the lipid component are embedded in a polymer matrix, preferably in the form of a molecular dispersion. The formulations can form emulsions in water or aqueous liquids.
AU2001266033A 2000-05-30 2001-05-29 Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base Abandoned AU2001266033A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10026699A DE10026699A1 (en) 2000-05-30 2000-05-30 Formulation based on heparin, glycosaminoglycan or heparinoid and use of the formulation and the formulation base
DE10026699 2000-05-30
PCT/EP2001/006115 WO2001091729A1 (en) 2000-05-30 2001-05-29 Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base

Publications (1)

Publication Number Publication Date
AU2001266033A1 true AU2001266033A1 (en) 2001-12-11

Family

ID=7644040

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001266033A Abandoned AU2001266033A1 (en) 2000-05-30 2001-05-29 Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base

Country Status (13)

Country Link
US (1) US7393840B2 (en)
EP (1) EP1284717B1 (en)
JP (1) JP5198708B2 (en)
CN (1) CN100391440C (en)
AT (1) ATE349202T1 (en)
AU (1) AU2001266033A1 (en)
BR (1) BR0111257A (en)
CA (1) CA2409828C (en)
DE (2) DE10026699A1 (en)
ES (1) ES2278750T3 (en)
NO (2) NO20025755D0 (en)
RU (1) RU2278658C2 (en)
WO (1) WO2001091729A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE329579T1 (en) * 1999-11-12 2006-07-15 Abbott Lab SOLID DISPERSION WITH RITONAVIR, FENOFIBRATE OR GRISEOFULVIN
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
DE10026698A1 (en) * 2000-05-30 2001-12-06 Basf Ag Self-emulsifying active ingredient formulation and use of this formulation
WO2002047696A1 (en) * 2000-12-16 2002-06-20 Aventis Pharma Deutschland Gmbh Use of low molecular heparin for treating osteoarthritis
GB0205868D0 (en) * 2002-03-13 2002-04-24 Univ Nottingham Polymer composite with internally distributed deposition matter
AU2003303301B2 (en) 2002-05-03 2008-08-07 Massachusetts Institute Of Technology Delta4,5 glycuronidase and uses thereof
SE0201922D0 (en) * 2002-06-20 2002-06-20 Ltp Lipid Technologies Provide Anticoagulant Composition
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
CA2543617A1 (en) * 2003-10-23 2005-05-12 The University Of Nottingham Preparing active polymer extrudates
ES2297516T3 (en) * 2003-12-02 2008-05-01 Universiteit Gent USE OF POLYSULPHATED ALGINATE IN CELLULAR MATRICES.
EP1537871A1 (en) * 2003-12-04 2005-06-08 Aventis Pharma S.A. Enoxaparin for the treatment of cancer
US7563780B1 (en) * 2004-06-18 2009-07-21 Advanced Cardiovascular Systems, Inc. Heparin prodrugs and drug delivery stents formed therefrom
JP5258144B2 (en) * 2004-12-21 2013-08-07 株式会社分子生理化学研究所 Method for producing solid coenzyme Q10 oral preparation with improved absorbability
US7691830B2 (en) * 2005-02-17 2010-04-06 Clive Elson Method and composition for treatment of a mucosal tissue disorder
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
US8802156B2 (en) 2007-11-14 2014-08-12 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
GB0812742D0 (en) 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
US20110305658A1 (en) * 2008-12-11 2011-12-15 L'oreal S.A. Lengthening mascara composition
WO2010113176A2 (en) * 2009-03-31 2010-10-07 Reliance Life Sciences Pvt. Ltd. Novel copolymers for controlled release delivery system
ES2363964B1 (en) 2009-11-20 2012-08-22 Gp Pharm, S.A. CAPSULES OF PHARMACEUTICAL ACTIVE PRINCIPLES AND ESTERS OF POLYINSATURATED FATTY ACIDS.
WO2011088418A2 (en) * 2010-01-15 2011-07-21 Mount Sinai School Of Medicine Inhibition of tnf-alpha induced activation of nfkb by pentosan polysulfate
WO2014142938A1 (en) * 2013-03-15 2014-09-18 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
US10897918B1 (en) * 2013-03-15 2021-01-26 Mccormick & Company, Incorporated Extrusion encapsulation with narrow particle size and shape distribution, high solubility, and low surface oil
JP6877996B2 (en) * 2016-12-27 2021-05-26 小林製薬株式会社 Topical composition
JP6877997B2 (en) * 2016-12-27 2021-05-26 小林製薬株式会社 Topical composition
CN113164430A (en) * 2018-06-03 2021-07-23 格莱科米拉治疗公司 Methods for preventing severe health consequences and/or tissue damage following exposure to ionizing radiation and/or chemotherapy
WO2021050320A1 (en) * 2019-09-09 2021-03-18 Harrow Ip, Llc Pharmaceutical compositions comprising heparinoids and methods for preparing thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1107041A (en) * 1913-10-25 1914-08-11 Benjamin H Cook Coupling device.
JPS58101311A (en) * 1981-12-11 1983-06-16 Toshiba Corp Polyphase voltage and current converting circuit
DE3331009A1 (en) * 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen METHOD FOR INCREASING THE ENTERAL RESORBABILITY OF HEPARIN OR. HEPARINOIDS AND THE SO AVAILABLE HEPARIN OR HEPARINOID PREPARATION
JPS6054313A (en) * 1983-09-01 1985-03-28 Terumo Corp Heparin composition absorbable through intestine
EP0318512B1 (en) 1986-08-18 1998-06-17 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
SE9200951D0 (en) * 1992-03-27 1992-03-27 Kabi Pharmacia Ab PHARMACEUTICAL COMPOSITION CONTAINING A DEFINED LIPID SYSTEM
US5346701A (en) * 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
SE9302135D0 (en) * 1993-06-18 1993-06-18 Kabi Pharmacia Ab NEW PHARMACEUTICAL COMPOSITION
CA2176927C (en) * 1993-11-17 2010-03-23 Seang H. Yiv Transparent liquid for encapsulated drug delivery
DE19531277A1 (en) 1995-08-25 1997-02-27 Basf Ag Use of lipids as an aid in the production of solid dosage forms by the melt extrusion process
FR2775188B1 (en) 1998-02-23 2001-03-09 Lipha IMMEDIATE RELEASE ORAL EXTENDED RELEASE GALENIC FORM COMPRISING AN ABSORPTION PROMOTING AGENT AND USE OF THE ABSORPTION PROMOTING AGENT
DE69917609T2 (en) 1998-03-05 2005-06-09 Phares Pharmaceutical Research N.V., Curaçao MEDICINES AND ITS USE
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents

Also Published As

Publication number Publication date
ES2278750T3 (en) 2007-08-16
NO20025759L (en) 2003-01-14
NO20025755D0 (en) 2002-11-29
NO20025759D0 (en) 2002-11-29
RU2278658C2 (en) 2006-06-27
JP2003534370A (en) 2003-11-18
DE50111738D1 (en) 2007-02-08
WO2001091729A1 (en) 2001-12-06
CN100391440C (en) 2008-06-04
ATE349202T1 (en) 2007-01-15
US7393840B2 (en) 2008-07-01
CA2409828C (en) 2010-08-03
JP5198708B2 (en) 2013-05-15
CA2409828A1 (en) 2001-12-06
BR0111257A (en) 2003-06-10
CN1450891A (en) 2003-10-22
EP1284717A1 (en) 2003-02-26
EP1284717B1 (en) 2006-12-27
DE10026699A1 (en) 2001-12-06
US20030161884A1 (en) 2003-08-28

Similar Documents

Publication Publication Date Title
AU2001266033A1 (en) Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base
BRPI0410956A (en) polyethylene oxide based films and drug delivery systems made from them
WO2000041538A3 (en) Dermal compositions
AU2001279631A1 (en) Self-emulsifying active substance formulation and use of this formulation
WO2004060405A8 (en) Tissue reactive compounds and compositions and uses thereof
WO2004112713A3 (en) Drug polymer complexes
ATE427760T1 (en) ERODABLE POLYMERS FOR INJECTION
AU2003281343A1 (en) Polymeric compositions containing polymers and ionic liquids
BR0106238B1 (en) molding dough having good blow molding capacity, as well as use of said molding dough and molded article containing it.
WO2005044224A3 (en) Drug delivery system based on polymer nanoshells
AU2003267581A1 (en) Drug delivery
ATE536869T1 (en) GLUCAN FILM BASED DRUG DELIVERY SYSTEMS
WO2004032862A3 (en) Cyclodextrin-based materials, compositions and uses related thereto
BR0307893A (en) Ophthalmic formulation with gum system
CA2430481A1 (en) Compositions for sustained delivery of hydrophobic drugs and process for the preparation thereof
KR930016091A (en) Method for preparing a solid dispersion of an almost water-insoluble drug
BRPI0416613A (en) composition and dosage form comprising an amphiphilic molecule as a suspension vehicle
CA2276661A1 (en) Personal wash liquid composition comprising low viscosity oils pre-thickened by non-antifoaming hydrophobic polymers
WO2005048930A3 (en) Surfactant-based gel as an injectable, sustained drug delivery vehicle
WO2008129106A3 (en) Nanoparticles comprising a cyclodextrin and a biologically active molecule and uses thereof
CA2444203A1 (en) Pet food composition containing semi-refined gelling agent
ES2168855T3 (en) PHARMACEUTICAL COMPOSITIONS IN THE FORM OF POLYMER MICROPARTICLES OBTAINED BY EXTRUSION AND SPHEROIDIZATION.
EP1110696A3 (en) Continuous process to prepare silicone compositions
AU2003256882A1 (en) Methods of drug delivery using sulphated chitinous polymers
DE60007074D1 (en) SULFATED PHOSPHATIDYLINOSITOLS, THEIR PRODUCTION AND USE